An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed solid tumor.
* Participant must meet at least one of the following criteria in the judgment of the investigator or sub-investigator:

  * Disease progression despite standard therapies
  * Progressive disease without any standard therapies established
  * Standard therapies are considered intolerable
* Eastern Cooperative Oncology Group performance status 0 or 1.
* Predicted life expectancy ≥ 12 weeks in the judgment of the investigator or sub-investigator.

Exclusion Criteria:

* Participant with ≥ Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective findings due to the toxicity attributable to prior treatment with antitumor effect (except alopecia).
* Participant who received a prior treatment intended for antitumor effect (medication, surgery, radiotherapy, etc.) within 4 weeks prior to the planned first day of study drug dosing (or participant who received mitomycin C or Nitrosourea within 6 weeks prior to the planned first day of study drug dosing).
* A major surgical procedure within 4 weeks prior to the planned first day of study drug dosing or a surgical procedure is planned during the course of the study.
* Participant who were treated with other investigational drug or medical device within 4 weeks prior to the planned first day of study drug dosing.
* Participant who has a history of organ transplantation.
* Participant with a brain metastasis with symptoms or requiring treatment.